Immunosuppressive Factors: Role in Cancer Development and Progression
暂无分享,去创建一个
E. Seregni | C. Botti | E. Bombardieri | A. Martinetti | L. Ferrari | L. Ferrari | Emilio Bombardieri | E. Bombardieri
[1] P. Gain,et al. Shedding of GD2 ganglioside in patients with retinoblastoma , 2009, International journal of cancer.
[2] T. Kucharzik,et al. Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL‐10 , 1997, Clinical and experimental immunology.
[3] C. Lombardo,et al. Structure, Function and Gene Expression of Epithelial Mucins , 1997, Tumori.
[4] J. Gribben,et al. Breast cancer–associated antigen, DF3/MUC1, induces apoptosis of activated human T cells , 1996, Nature Medicine.
[5] F. Shanahan,et al. Regional immunosuppression in esophageal squamous cancer: evidence from functional studies with matched lymph nodes. , 1996, Journal of immunology.
[6] L. Bover,et al. Identification and characterization of a 14 kDa immunosuppressive protein derived from IIB-MEL-J, a human melanoma cell line. , 1996, Cellular and molecular biology.
[7] A. Spigelman,et al. Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac , 1996, Diseases of the colon and rectum.
[8] M. Bertagnolli,et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. , 1996, Cancer research.
[9] L. Wakefield,et al. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[10] D. Mercola,et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[11] K. Patel,et al. Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. , 1995, British Journal of Cancer.
[12] F. Sharom,et al. Gangliosides are potent immunosuppressors of IL-2-mediated T-cell proliferation in a low protein environment. , 1995, Immunology.
[13] P. Krammer,et al. Selective suppression of cytokine secretion in patients with small-cell lung cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] P. Isakson,et al. Characterization of a monoclonal antibody that neutralizes the activity of prostaglandin E2. , 1995, Journal of immunology.
[15] W. Jonat,et al. Transforming Growth Factor β2 (TGF-β2) Levels in Plasma of Patients with Metastatic Breast Cancer Treated with Tamoxifen , 1995 .
[16] W. Gross,et al. Determination of transforming growth factor β2 in human blood samples by ELISA , 1995 .
[17] J. Kim,et al. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. , 1995, Journal of immunology.
[18] M. Anscher,et al. Elevated Plasma Transforming Growth Factor-β1 Levels in Breast Cancer Patients Decrease After Surgical Removal of the Tumor , 1995, Annals of surgery.
[19] S. Winawer,et al. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[20] H. Poulsen,et al. Transforming growth factor and cancer , 1995 .
[21] E. Seregni,et al. Biochemical characteristics and clinical applications of alpha-fetoprotein isoforms. , 1995, Anticancer research.
[22] S. Isoe,et al. Secretion of Transforming Growth Factor-1 and -2 by Malignant Glioma Cells , 1995 .
[23] R. Kurzrock,et al. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. , 1995, Blood.
[24] E. Papavassiliou,et al. Prostaglandin E2 down-regulates the expression of HLA-DR antigen in human colon adenocarcinoma cell lines. , 1995, Biochemistry.
[25] A. Melman,et al. Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer , 1995, Nature Medicine.
[26] L. Marnett. Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. , 1995, Preventive Medicine.
[27] K. Bost,et al. Lymphokine mRNA expression by transplantable murine B lymphocytic malignancies. Tumor-derived IL-10 as a possible mechanism for modulating the anti-tumor response. , 1995, Journal of immunology.
[28] K. Kikuchi,et al. Transforming growth factor beta 1 as a prognostic factor in pulmonary adenocarcinoma. , 1994, Journal of clinical pathology.
[29] C. J. Burger,et al. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. , 1994, Journal of immunology.
[30] A. Nakane,et al. Evidence That α-Fetoprotein Suppresses the Immunological Function in Transgenic Mice , 1994 .
[31] K. Pummer,et al. Serum immunosuppressive acid protein predicts lymph node metastases in patients with renal cell carcinoma. , 1994, British journal of urology.
[32] S. Koyama. Immunosuppressive Effect of Shedding Intercellular Adhesion Molecule 1 Antigen on Cell‐mediated Cytotoxicity against Tumor Cells , 1994, Japanese journal of cancer research : Gann.
[33] V. Blanckaert,et al. Differential growth factor production, secretion, and response by high and low metastatic variants of B16BL6 melanoma. , 1993, Cancer research.
[34] M. Chen,et al. Interleukin‐10 production by human carcinoma cell lines and its relationship to interleukin‐6 expression , 1993, International journal of cancer.
[35] A. Gritzapis,et al. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine‐activated killer cell function in patients with breast cancer , 1993, Cancer.
[36] C. Melief,et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. , 1993, Journal of immunology.
[37] D. Rifkin,et al. TGF-β: Structure, Function, and Formation , 1993, Thrombosis and Haemostasis.
[38] H. Moses,et al. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[39] R. Bast,et al. Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer , 1992, Cancer.
[40] S. Itzkowitz,et al. Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. , 1992, Cancer research.
[41] Y. Matsuzawa,et al. Elevated Levels of Plasma Transforming Growth Factor‐β in Patients with Hepatocellular Carcinoma , 1992, Japanese journal of cancer research : Gann.
[42] Y. Kim,et al. Mucin associated Tn and sialosyl-Tn antigen expression in colorectal polyps. , 1992, Gut.
[43] G. Tosato,et al. IL-10 inhibits human T cell proliferation and IL-2 production. , 1992, Journal of immunology.
[44] M. Thun,et al. Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.
[45] Y. Hinoda,et al. Detection of circulating intercellular adhesion molecule‐1 antigen in malignant diseases , 1991, Clinical and experimental immunology.
[46] H. Muller,et al. A role for prostaglandins in the suppression of cutaneous cellular immunity and tumour development in benzo(a)pyrene‐ but not dimethylbenz(a)anthracene‐treated mice , 1991, Clinical and experimental immunology.
[47] S. Law,et al. Antigen shedding and metastasis of tumour cells , 1991, Clinical and experimental immunology.
[48] S. Hakomori,et al. Expression of Tn, sialosyl Tn, and T antigens in human pancreas. , 1991, Gastroenterology.
[49] A. Fauci,et al. Transforming growth factor-beta suppresses human B lymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. , 1991, Journal of immunology.
[50] D. Berg,et al. Immune dysfunction in mice with plasmacytomas. I. Evidence that transforming growth factor-beta contributes to the altered expression of activation receptors on host B lymphocytes. , 1991, Journal of immunology.
[51] M. Colombo,et al. The high lysability by lak cells of colon‐carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM‐1, LFA‐3, NCA and a less‐differentiated phenotype , 1991, International journal of cancer.
[52] J. Neoptolemos,et al. Arachidonic acid and docosahexaenoic acid are increased in human colorectal cancer. , 1991, Gut.
[53] H. Fujiwara,et al. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. , 1991, Journal of immunology.
[54] M. Kasahara,et al. The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I. Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF. , 1991, Journal of immunology.
[55] J. Viñuela,et al. Antigen shedding vs. development of natural suppressor cells as mechanism of tumor escape in mice bearing ehrlich tumor , 1991, International journal of cancer.
[56] I. Scott,et al. A comparison of the growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumours. , 1991, British Journal of Cancer.
[57] Y. Tomita,et al. Expression of intercellular adhesion molecule‐1 (ICAM‐1) on renal‐cell cancer: Possible significance in host immune responses , 1990, International journal of cancer.
[58] A. Levinson,et al. Immunoregulatory role of transforming growth factor beta (TGF-beta) in development of killer cells: comparison of active and latent TGF-beta 1 , 1990, The Journal of experimental medicine.
[59] S. Hakomori,et al. Sialosyl‐Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients , 1990, Cancer.
[60] H. Kusaka,et al. Relationship between blood plasma prostaglandin E2 and liver and lung metastases in colorectal cancer , 1990, Diseases of the colon and rectum.
[61] D. Hayes,et al. DF3 antigen, a human epithelial cell mucin, inhibits adhesion of eosinophils to antibody-coated targets. , 1990, Journal of immunology.
[62] S. Kim,et al. Interference with immune response at the level of generating effector cells by tumor-associated haptoglobin. , 1990, Journal of the National Cancer Institute.
[63] H. Moses,et al. The cell biology of transforming growth factor β , 1990 .
[64] M. Ligtenberg,et al. Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. , 1990, The Journal of biological chemistry.
[65] S. Ferrone,et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. , 1990, Cancer research.
[66] H. Koeppen,et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[67] J. Cambier,et al. Transforming growth factor beta 1 has differential effects on B cell proliferation and activation antigen expression. , 1990, Journal of immunology.
[68] J. Jimenez,et al. Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. , 1990, Cancer research.
[69] K. Frei,et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. , 1989, Journal of immunology.
[70] R. Zinkernagel,et al. Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. , 1989, Journal of immunology.
[71] H. Lin,et al. Regulation of Systemic Macrophage IL‐1 Gene Transcription: The Involvement of Tumor‐Derived Macrophage Growth Factor, CSF‐1 , 1989, Journal of leukocyte biology.
[72] J. Addonizio,et al. Immunosuppressive factor derived from renal cancer cells. , 1989, Urology.
[73] H. Baumann,et al. Hepatocyte-stimulating factor III shares structural and functional identity with leukemia-inhibitory factor. , 1989, Journal of immunology.
[74] C. Giampaolo,et al. Monoclonal antibody to SER immune suppressor detects polymeric forms of haptoglobin. , 1989, Hybridoma.
[75] M. J. Ehrke,et al. Modification of host antitumor defense mechanisms in mice by progressively growing tumor. , 1989, Cancer research.
[76] J. Hamada,et al. Growth-associated shedding of a tumor antigen (CE7) detected by a monoclonal antibody. , 1989, Cancer research.
[77] T. Kameda,et al. Analysis of site of action of a choriocarcinoma-derived immunoregulatory factor on IL-2-mediated T cell responses. , 1989, Journal of reproductive immunology.
[78] Q. Zhou,et al. Pre‐ and postoperative sequential study on the immunosuppressive activity of serum and cell‐free skin bleb fluid of patients with lung cancer and esophageal cancer , 1989, Journal of surgical oncology.
[79] P. Guillou,et al. Suppression of the generation of lymphokine-activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumour cell lines. , 1989, British Journal of Cancer.
[80] M. Vadas,et al. TGF beta down-regulates TLiSA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells. , 1989, Immunology.
[81] T. Kameda,et al. Trophoblast‐Derived Immunoregulatory Factor: Demonstration of the Biological Function and the Physicochemical Characteristics of the Factor Derived From Choriocarcinoma Cell Lines , 1989, American journal of reproductive immunology.
[82] A. Telerman,et al. Hybridoma-derived human suppressor factors: differential effects on mouse lymphocytes. , 1989, Hybridoma.
[83] N. Kay,et al. Malignant chronic lymphocytic leukemia B cells elaborate soluble factors that down‐regulate T cell and NK function , 1989, American journal of hematology.
[84] E. Oldfield,et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. , 1989, Journal of neurosurgery.
[85] L. Ulsh,et al. Immunosuppressive activity of human neuroblastoma tumor gangliosides , 1989, International journal of cancer.
[86] N. Tribolet,et al. Transforming growth factor‐β2 down‐regulates HLA‐DR antigen expression on human malignant glioma cells. , 1988 .
[87] S. Wahl,et al. Bacterial cell wall-induced immunosuppression. Role of transforming growth factor beta , 1988, The Journal of experimental medicine.
[88] S. Normann,et al. Isolation of a low molecular weight inhibitor of lymphocyte proliferation from tumorous ascites. , 1988, Journal of immunology.
[89] M. Boyd,et al. Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate, and ovarian tumors. , 1988, Cancer research.
[90] C. Gahmberg,et al. CD11a-c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing. , 1988, Journal of immunology.
[91] M. Sporn,et al. Deactivation of macrophages by transforming growth factor-β , 1988, Nature.
[92] G. I. Bell,et al. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. , 1988, Journal of immunology.
[93] R. Suzuki,et al. Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells. , 1988, Journal of immunology.
[94] R. Snyderman,et al. Human IFN-gamma production is inhibited by a synthetic peptide homologous to retroviral envelope protein. , 1988, Journal of immunology.
[95] G. Wong,et al. Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. , 1988, Journal of immunology.
[96] I. Chaudry,et al. Prostaglandin E2 depresses antigen-presenting cell function of peritoneal macrophages. , 1988, The Journal of surgical research.
[97] A. Roberts,et al. Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. , 1988, Journal of immunology.
[98] S. Hirohashi,et al. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2----6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. , 1988, Cancer research.
[99] T. Springer,et al. Functional evidence that intercellular adhesion molecule‐1 (icam‐1) is a ligand for lfa‐1d‐ependent adhesion in t cell‐mediated cytotoxicity , 1988, European journal of immunology.
[100] L. Bergelson,et al. Sialylated lactosylceramides. Possible inducers of non-specific immunosuppression and atherosclerotic lesions. , 1988, European journal of biochemistry.
[101] D. Hayes,et al. Genetically determined polymorphism of the circulating human breast cancer-associated DF3 antigen , 1988 .
[102] A. Cochran,et al. Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2. , 1988, Cellular immunology.
[103] P. Cornaglia-Ferraris,et al. Purification to homogeneity and biochemical characterization of two suppressor factors from human malignant T-cells. , 1988, Biochemical and biophysical research communications.
[104] T. Springer,et al. ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells , 1988, Nature.
[105] Timothy A. Springer,et al. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1) , 1987, Cell.
[106] T. Roszman,et al. Inhibition of lymphocyte responsiveness by a glial tumor cell-derived suppressive factor. , 1987, Journal of Neurosurgery.
[107] Y. Hirabayashi,et al. Detection of ganglioside GM2 in sera and tumor tissues of hepatoma patients. , 1987, Japanese journal of cancer research : Gann.
[108] S. Eto,et al. Effect of immunosuppressive factors produced by adult T cell leukemia cells on B cell responses. , 1987, Japanese journal of cancer research : Gann.
[109] J. Monson,et al. Lymphokine activated killer (LAK) cells in patients with gastrointestinal cancer. , 1987, Gut.
[110] T. Espevik,et al. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha , 1987, The Journal of experimental medicine.
[111] R. Snyderman,et al. A synthetic peptide homologous to the envelope proteins of retroviruses inhibits monocyte-mediated killing by inactivating interleukin 1. , 1987, Journal of immunology.
[112] S. Ju,et al. An analogy between fetal haptoglobin and a potent immunosuppressant in cancer. , 1987, Cancer research.
[113] P. Papenhausen,et al. HL-T, a new cell line derived from HL-60 promyelocytic leukemia cell cultures expressing terminal transferase and secreting suppressor activity. , 1987, Blood.
[114] G. Atlante,et al. Immunosuppressive Acidic Protein (Iap) and Ca 125 Assays in Detection of Human Ovarian Cancer: Preliminary Results , 1987, The International journal of biological markers.
[115] Y. Sugiyama,et al. Effects of serum immunosuppressive factors on antitumor cytotoxicity of interleukin 2‐induced lymphocytes , 1987, Journal of surgical oncology.
[116] L. D. Bergel'son,et al. [Glycosphingolipids and antitumor immunity]. , 1987, Eksperimental'naia onkologiia.
[117] D. Kufe,et al. Identification of a family of high molecular weight tumor-associated glycoproteins. , 1987, Journal of immunology.
[118] K. Frei,et al. T cell suppressor factor from human glioblastoma cells is a 12.5‐kd protein closely related to transforming growth factor‐beta. , 1987, The EMBO journal.
[119] K. Matsunaga,et al. Purification and characterization of immunosuppressive (IS) substance obtained from ascitic fluids of patients with gastrointestinal cancer. , 1987, Clinical biochemistry.
[120] F. Robertson,et al. Characterization of an immunosuppressive factor derived from colon cancer cells. , 1987, Journal of immunology.
[121] D. Stephany,et al. Generation of activated killer cells in tumor‐bearing hosts , 1987, International journal of cancer.
[122] R. Snyderman,et al. Inhibition of human natural killer cell activity by a synthetic peptide homologous to a conserved region in the retroviral protein, p15E. , 1987, Journal of immunology.
[123] S. Feig,et al. Shedding of GD2 ganglioside by human neuroblastoma , 1987, International journal of cancer.
[124] D. H. van den Eijnden,et al. Specific inhibition of human natural killer cell‐mediated cytotoxicity by sialic acid and sialo‐oligosaccharides , 1986, International journal of cancer.
[125] J. Roche,et al. Characterization of an immunosuppressive factor from malignant ascites that resembles a factor induced in vitro by carcinoembryonic antigen. , 1986, Journal of immunology.
[126] S. Eto,et al. Immunosuppressive factors from adult T-cell leukemia cells. , 1986, Cancer research.
[127] E. Kawasaki,et al. Inducible production of human macrophage growth factor, CSF-1 , 1986 .
[128] Michael Loran Dustin,et al. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. , 1986, Journal of immunology.
[129] Michael Loran Dustin,et al. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). , 1986, Journal of immunology.
[130] M. Sporn,et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. , 1986, Journal of immunology.
[131] S. Rosenberg,et al. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells. , 1986, Journal of immunology.
[132] R. Snyderman,et al. Suppression of the respiratory burst of human monocytes by a synthetic peptide homologous to envelope proteins of human and animal retroviruses. , 1986, Journal of immunology.
[133] J. Jessup,et al. Tumor-derived suppressor factors (TDSFs) in normal and neoplastic colon and rectum. , 1986, The Journal of surgical research.
[134] M. Sporn,et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth , 1986, The Journal of experimental medicine.
[135] M. Sporn,et al. Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells , 1986, The Journal of cell biology.
[136] S. Miescher,et al. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. , 1986, Journal of immunology.
[137] B. Cohen,et al. Suppression by Alpha‐Fetoprotein of Murine Natural Killer Cell Activity Stimulated in Vitro and in Vivo by Interferon and Interleukin 2 , 1986, Scandinavian journal of immunology.
[138] D. Tweardy,et al. A suppressor lymphokine produced by human T leukemia cell lines. Partial characterization and spectrum of activity against normal and malignant hemopoietic cells , 1986, The Journal of experimental medicine.
[139] D. Kufe,et al. Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas. , 1985, Journal of immunology.
[140] C. Hardy,et al. Review: Hemopoietic Alterations of Cancer , 1985 .
[141] C. Van Waes,et al. Multiple cancers. Tumor burden permits the outgrowth of other cancers , 1985, The Journal of experimental medicine.
[142] R. Snyderman,et al. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. , 1985, Science.
[143] Y. Osaki,et al. Immunosuppressive factor from the spleen in gastric cancer patients , 1985, Cancer.
[144] R. Snyderman,et al. Successful tumour immunotherapy: possible role of antibodies to anti-inflammatory factors produced by neoplasms. , 1985, Clinical and experimental immunology.
[145] A. Thor,et al. Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions. , 1985, Cancer research.
[146] L. Ulsh,et al. Modulation of the immune response by gangliosides. Inhibition of adherent monocyte accessory function in vitro. , 1984, The Journal of clinical investigation.
[147] D. H. Pluznik,et al. Inhibition of interleukin-2-dependent cytotoxic T-lymphocyte growth by gangliosides. , 1984, Cellular immunology.
[148] D. Marcus,et al. A review of the immunogenic and immuno-modulatory properties of glycosphingolipids. , 1984, Molecular immunology.
[149] L. Thiry,et al. Study of the expression of a glycoprotein of retroviral origin in the plasma of patients with hematologic disorders and in the plasma of normal individuals , 1984 .
[150] N. de Tribolet,et al. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. , 1984, Journal of immunology.
[151] Y. Shibata,et al. Cultured Human Monocytes, Granulocytes and a Monoblastoid Cell Line (THP‐1) Synthesize and Secrete Immunosuppressive Acidic Protein (a Type of α1‐Acid Glycoprotein) , 1984, Microbiology and immunology.
[152] M. Sporn,et al. Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[153] L. Ulsh,et al. Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. , 1983, Cancer research.
[154] H. Wigzell,et al. Cellular and genetic restrictions in the immunoregulatory activity of alpha-fetoprotein. III. Role of the MLC-stimulating cell population in alpha-fetoprotein-induced suppression of T cell-mediated cytotoxicity. , 1982, Journal of immunology.
[155] G. R. Dodge,et al. Prostaglandin E inhibits the production of human interleukin 2 , 1982, The Journal of experimental medicine.
[156] M. Sporn,et al. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[157] Y. Shibata,et al. Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. , 1981, Cancer research.
[158] L. Marnett,et al. Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. , 1981, Prostaglandins.
[159] E. Hoover,et al. Immunosuppressive properties of a virion polypeptide, a 15,000-dalton protein, from feline leukemia virus. , 1979, Cancer research.
[160] E. Hoover,et al. Abrogation of lymphocyte blastogenesis by a feline leukaemia virus protein , 1978, Nature.
[161] T. Żebro,et al. Prostaglandins from tumours of human large bowel. , 1977, British Journal of Cancer.
[162] H. Wigzell,et al. α-Fetoprotein induces suppressor T cells in vitro , 1977, Nature.
[163] E. Alpert,et al. The effect of purified α-fetoprotein on in vitro assays of cell-mediated immunity , 1977 .
[164] H. Kress,et al. Suppression of the primary cell-mediated immune response by human alpha1-fetoprotein in vitro. , 1977, Cellular immunology.
[165] W. J. Esselman,et al. Modulation of the immune response by antigen-reactive lymphocytes after cultivation with gangliosides. , 1975, Journal of immunology.
[166] T. Tomasi,et al. Suppression of the immune response by alpha-fetoprotein on the primary and secondary antibody response , 1975, The Journal of experimental medicine.
[167] M. Netsky,et al. DEPRESSED CELL-MEDIATED IMMUNITY IN PATIENTS WITH PRIMARY INTRACRANIAL TUMORS , 1972, The Journal of experimental medicine.
[168] M. Reddish,et al. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 , 1998, Nature Medicine.
[169] P. Ferrari,et al. Cell-mediated immunity in breast cancer patients. , 1996, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[170] J. Keski‐Oja,et al. Transforming growth factor-beta system and its regulation by members of the steroid-thyroid hormone superfamily. , 1996, Advances in cancer research.
[171] K. Cowan,et al. Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[172] T. Chao,et al. Effects of indomethacin on lymphokine-activated killer cell activities in cancer patients. , 1995, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[173] D. Kingsley,et al. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. , 1994, Genes & development.
[174] D. Sulitzeanu. Immunosuppressive factors in human cancer. , 1993, Advances in cancer research.
[175] K. Takatsuki,et al. Ganglioside-induced inhibition of in vivo immune response in mice. , 1992, Life sciences.
[176] S. Ladisch,et al. Immunosuppression by human gangliosides. II. Carbohydrate structure and inhibition of human NK activity. , 1992, Cellular immunology.
[177] R T Prehn,et al. The inhibition of tumor growth by tumor mass. , 1991, Cancer research.
[178] Y. Kim,et al. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. , 1989, Cancer research.
[179] M. Abolhassani,et al. Purification of a suppressor lymphokine (SL) from a human T-cell line. , 1989, Immunological investigations.
[180] M. Ponzoni,et al. A human acute leukemia-derived T-cell line produces two inhibitor factors which suppress lymphocyte proliferation: characterization and purification of the molecules. , 1988, Lymphokine research.
[181] J. Walker,et al. Role of a SER immune suppressor in immune surveillance. , 1988, Immunology.
[182] A. F. Williams,et al. The immunoglobulin superfamily--domains for cell surface recognition. , 1988, Annual review of immunology.
[183] G. Granger,et al. Heterogeneity of soluble suppressor factors in rat malignant ascites. , 1988, Oncology.
[184] J. Williams,et al. Biological properties of suppressive E‐receptor factor on lymphokine function , 1987, European journal of immunology.
[185] J. Schlom,et al. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. , 1984, Hybridoma.
[186] R. Evans,et al. Journal of Leukocyte Biology 49:474-482 (1991) Tumor-Derived Products Induce Il-i a, Il-i b, Tnf a, and 11-6 Gene Expression in Murine Macrophages: Distinctions Between Tumor- and Bacterial Endotoxin-Induced , 2022 .
[187] V. Steele,et al. Chemoprevention of Colon Carcinogenesis by Sulindac , a Nonsteroidal Anti-inflammatory Agent 1 , 2022 .